Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
501-520 of 1,782 trials

Ocular Myasthenia Gravis: Corticosteroids and Rituximab Treatment

We are studying whether immediate corticosteroid therapy combined with rituximab can help prevent worsening symptoms in patients with ocular myasthenia gravis. This trial looks at various health outcomes over two years.

Myasthenia Gravis6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyRheumatology

Rheumatoid Arthritis: New Biosimilar Drug Study

We are comparing a new biosimilar drug to Orencia® for patients with moderate to severe rheumatoid arthritis already taking methotrexate. The study will look at effectiveness, safety, and how the body reacts to the treatment.

Rheumatoid Arthritis1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology

Heart Failure: Colchicine and Thiamine Study

We are studying whether colchicine and thiamine can help improve heart health in people with heart failure due to ischemic heart disease. The trial looks at their effects on serious heart-related events and hospital visits.

Heart Failure>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Prostate Cancer: 12-Month Treatment Study

We are studying whether stopping a treatment for prostate cancer after 12 months is as effective as continuing it. This may help reduce side effects and costs for patients with low-volume metastatic castration-sensitive prostate cancer.

Low-Volume Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

Rectal Cancer Treatment: Comparing Therapies for Older Patients

We are studying whether a conventional treatment approach is safer and more effective than total neoadjuvant therapy for older patients with locally advanced rectal cancer. This trial will also look at quality of life and healthcare resource use.

Rectal Cancer6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Mantle-Cell Lymphoma: Glofitamab with Venetoclax and Zanubrutinib

We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.

Mantle-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ALK Positive Non-Small Cell Lung Cancer: Chemotherapy Plus Lorlatinib

We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Familial Mediterranean Fever: On-Demand Anakinra Treatment

We are studying whether on-demand Anakinra can help patients with colchicine-resistant FMF manage painful attacks without daily therapy. This trial compares its effectiveness to standard pain management options.

Familial Mediterranean Fever>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInfectious DiseasesInternal MedicineRheumatology

Penile Cancer: Carboplatin, Paclitaxel, and Pembrolizumab Study

We are studying a combination of chemotherapy and immunotherapy for patients with locoregionally advanced penile cancer. The goal is to see if this treatment can effectively shrink tumors before surgery and to assess its safety.

Locoregionally Advanced Penile Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Advanced Gastric Cancer: EXL01 with Nivolumab and FOLFOX

We are studying a new treatment combination for patients with advanced gastric cancer to see if it improves response rates and safety. This trial focuses on those with a specific biomarker to better understand treatment effectiveness.

Metastatic Gastric Adenocarcinoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Lung Cancer: Selpercatinib Study

We are testing a new treatment called selpercatinib for patients with RET fusion-positive non-small cell lung cancer. The goal is to see if it improves outcomes compared to a placebo.

RET Fusion-Positive Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Pain Relief for Kids: Fentanyl vs. Ketamine vs. Morphine

We are studying whether intranasal fentanyl or ketamine is more effective than oral morphine for reducing pain in children with limb injuries. This trial involves children aged 2 to 17 in emergency departments.

Limb InjuriesUrgency>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Prostate Cancer: Intermittent vs. Continuous Hormone Therapy

We are studying whether intermittent hormone therapy can maintain effectiveness and improve daily life for men with advanced prostate cancer. This trial compares it to continuous hormone therapy to see which is better for patients.

Hormone-sensitive Metastatic Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Mycobacterium Xenopi Infection: ARIKAYCE Inhalation Treatment

We are studying whether adding ARIKAYCE to standard treatment helps people with Mycobacterium xenopi lung infections clear the infection more effectively. The trial will measure how quickly and effectively the treatment works compared to standard care alone.

Mycobacterium xenopi Pulmonary Infection>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Chronic Kidney Disease: Teriparatide for Bone Health

We are studying whether teriparatide can improve bone metabolism in patients with chronic kidney disease and adynamic bone disorder. This trial compares the effects of treatment to no treatment at all.

Adynamic Bone Disorder>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesNephrologyOrthopedics and Traumatology

Staphylococcus Aureus Bacteraemia: Bensylpenicillin vs. Cloxacillin

We are comparing two antibiotics to see which one works better for patients with a specific bacterial infection. The study looks at treatment outcomes, relapse rates, and side effects.

Staphylococcus aureus Bacteraemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Rectal Adenocarcinoma: Contact X-Ray Brachytherapy Study

We are studying whether adding contact X-ray brachytherapy to standard treatment can help preserve the rectum and improve survival in patients with intermediate substage rectal adenocarcinoma. We will also assess its impact on quality of life and side effects.

Rectal Adenocarcinoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Alectinib Dosing: Standard vs. Personalized Approach

We are comparing standard alectinib dosing to a personalized dosing method based on blood levels for patients with specific alectinib concentrations. The goal is to see if personalized dosing improves treatment outcomes and safety.

ALK Positive Non-Small Cell Lung Cancer1-2 yearsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Liver Cancer: Fecal Microbiota Transfer Study

We are investigating whether fecal microbiota transfer can help liver cancer patients who are resistant to standard treatments. The study aims to improve immune response and overall survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHepatologyInternal MedicineOncology

Oocyte Donation: Corifollitropin alfa vs. Daily rFSH

We are studying whether Corifollitropin alfa can help increase the number of eggs collected from oocyte donors compared to standard daily treatments. This trial involves women using hormone suppression to improve egg quality.

Female Infertility1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteGynecology and Obstetrics